Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T64117 |
BRD4-BD1-IN-2
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
BRD4-BD1-IN-2 是一种具有选择性和有效性的 BRD4-BD1 抑制剂,IC50 值为 2.51 µM ,是对 BRD4-BD2 抑制活性的 20 倍。BRD4-BD1-IN-2 可用于研究心血管疾病和癌症相关疾病。 | |||
T63707 |
BRD4-BD1/2-IN-2
|
||
BRD4-BD1/2-IN-2 是 BRD4-BD2 的有效抑制剂,能够作用于 BRD4 BD2 (IC50<0.5 nM) 和 BRD4 BD1 (IC50<300 nM)。 | |||
T61791 |
BRD4-BD1/2-IN-1
|
||
BRD4-BD1/2-IN-1 is a highly effective inhibitor of BRD4, specifically targeting the BRD4 BD-1 and BRD4 BD-2 domains with IC 50 values of <100 nM each (US20150148375A1, compound 5) [1]. | |||
T10773 |
CF53
|
Epigenetic Reader Domain; CDK | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
CF53 是一种高效、选择性、可口服的 BET 抑制剂,对 BRD4 BD1 的 Ki 值为 <1 nM,Kd 值为 2.2 nM,IC50 值为 2 nM;CF53 对 BRD2,BRD3,BRD4 和 BRDT BET 蛋白的 BD1 和 BD2 两个结构域都有高亲和性,对其选择性远高于非含溴结构域 BET 蛋白。CF53 在体外和体内都具有显著的抗肿瘤活性。 | |||
T10520 |
BET-IN-2
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
BET-IN-2 is a BET inhibitor (IC50: 52 nM for BRD4-BD1). | |||
T36628 |
PROTAC BRD4 Degrader-8
PROTAC BRD4 Degrader-8 |
PROTACs | PROTAC |
PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells[1]. PROTAC BRD4 Degrader-8 (compound 8; 6 days) inhibits the proliferation of PC3 prostate cancer cells, with an IC50 of 28 nM[1].PROTAC BRD4 Degrader-8 (4 h) suppresses MYC gene transcript in MV4-11 AML cells, with an IC50 of 11 nM[1].PROTAC BRD4 Degrader-8 (4 h) potently degra... | |||
T36103 |
TW9
TW9 |
||
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μM) and for HDAC1 over HDAC2 (IC50= 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistica... |